| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/02/2003 | EP1268854A1 High specificity marker detection |
| 01/02/2003 | EP1268839A1 Beta-glucans from filamentous fungi |
| 01/02/2003 | EP1268820A2 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 01/02/2003 | EP1268812A2 Vectors for gene therapy |
| 01/02/2003 | EP1268803A2 Bi-functional cancer treatment agents |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268800A2 Mucin-1 specific binding members and methods of use thereof |
| 01/02/2003 | EP1268799A2 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268792A2 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 01/02/2003 | EP1268791A2 Brca-1 regulators and methods of use |
| 01/02/2003 | EP1268790A1 Gene coding for erbin, and diagnostic and therapeutic uses thereof |
| 01/02/2003 | EP1268787A2 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 01/02/2003 | EP1268784A2 Genes involved in intestinal inflammatory diseases and use thereof |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268768A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/02/2003 | EP1268764A2 Method for obtaining nucleic acids from an environment sample |
| 01/02/2003 | EP1268761A2 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
| 01/02/2003 | EP1268760A1 Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments |
| 01/02/2003 | EP1268759A2 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 01/02/2003 | EP1268756A2 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 01/02/2003 | EP1268753A2 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 01/02/2003 | EP1268747A1 Detection of immunological memory, t-cell conjugates for pathology imaging and therapy |
| 01/02/2003 | EP1268746A2 PRODUCTION OF TcR GAMMA DELTA T CELLS |
| 01/02/2003 | EP1268559A1 Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation |
| 01/02/2003 | EP1268558A1 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268550A2 Human fap-alpha-specific antibodies |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268547A2 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 01/02/2003 | EP1268544A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 01/02/2003 | EP1268543A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268542A2 Therapeutic anti-melanoma compounds |
| 01/02/2003 | EP1268541A1 7 human ovarian and ovarian cancer associated proteins |
| 01/02/2003 | EP1268540A2 Proteins amf-1 to amf-10 and nucleic acids encoding same |
| 01/02/2003 | EP1268539A2 Estrogen-regulated unconventional myosin-related protein: compositions and methods of use |
| 01/02/2003 | EP1268537A1 Crystal structure of the (aml1 runt domain)/(cbfbeta) heterodimer and the ternary complex with dna |
| 01/02/2003 | EP1268536A1 Tcf responsive element |
| 01/02/2003 | EP1268534A2 Peptides binding to non-acetylated h3 and h4 histones for cancer therapy |
| 01/02/2003 | EP1268528A2 Human genes and expression products |
| 01/02/2003 | EP1268526A2 Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/02/2003 | EP1268524A2 Binding peptides for carcinoembryonic antigen (cea) |
| 01/02/2003 | EP1268522A2 Novel lhrh-antagonists, production and use thereof as medicament |
| 01/02/2003 | EP1268510A2 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268507A1 Antisense modulation of e2f transcription factor 1 expression |
| 01/02/2003 | EP1268504A1 Nucleoside compounds and uses thereof |
| 01/02/2003 | EP1268495A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268494A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268493A1 Phosphoramidate prodrugs |
| 01/02/2003 | EP1268489A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268481A2 Kinase inhibitors as therapeutic agents |
| 01/02/2003 | EP1268480A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/02/2003 | EP1268476A1 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| 01/02/2003 | EP1268473A1 Oxazole derivatives and their uses as tyrosine kinase inhibitors |
| 01/02/2003 | EP1268472A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/02/2003 | EP1268471A1 N-heterocyclic derivatives as nos inhibitors |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268448A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases |
| 01/02/2003 | EP1268445A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
| 01/02/2003 | EP1268444A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrmidines as antineoplastic agents |
| 01/02/2003 | EP1268437A1 Inhibitors of protein kinases |
| 01/02/2003 | EP1268431A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| 01/02/2003 | EP1268430A1 Chemical complex compprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 01/02/2003 | EP1268429A1 Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same |
| 01/02/2003 | EP1268425A2 Carbamate caspase inhibitors and uses thereof |
| 01/02/2003 | EP1268416A1 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses |
| 01/02/2003 | EP1268415A1 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds |
| 01/02/2003 | EP1268414A1 Ceramide derivatives and method of use |
| 01/02/2003 | EP1268405A1 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents |
| 01/02/2003 | EP1268404A1 Malonamic acids and derivatives thereof as thyroid receptor ligands |
| 01/02/2003 | EP1268389A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/02/2003 | EP1268387A2 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/02/2003 | EP1268306A1 Inverted aerosol dispenser |
| 01/02/2003 | EP1268096A1 Extrusion die |
| 01/02/2003 | EP1267954A1 Medical devices suitable for gene therapy regimens |
| 01/02/2003 | EP1267946A2 Nanocapsule encapsulation system and method |
| 01/02/2003 | EP1267945A2 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor |
| 01/02/2003 | EP1267944A1 Systemic gene delivery vehicles for the treatment of tumors |
| 01/02/2003 | EP1267943A2 Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof |
| 01/02/2003 | EP1267940A1 Compounds for targeting |
| 01/02/2003 | EP1267939A2 Polyglutamic acid-camptothecin conjugates and methods of preparation |
| 01/02/2003 | EP1267935A2 Novel treatment for eye disease |
| 01/02/2003 | EP1267934A2 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 01/02/2003 | EP1267933A2 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 01/02/2003 | EP1267929A2 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 01/02/2003 | EP1267928A2 Methods for immunostimulation using bispecific binding agents for the fc receptor of immunoglobulin a and for cancer cells or infectious antigen |
| 01/02/2003 | EP1267927A1 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 |
| 01/02/2003 | EP1267924A2 Immunotherapeutic methods and compositions |
| 01/02/2003 | EP1267918A1 Method of treatment using ligand-immunogen conjugates |
| 01/02/2003 | EP1267915A2 Methods of treating diseases with activated protein c |
| 01/02/2003 | EP1267913A2 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 01/02/2003 | EP1267910A2 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 01/02/2003 | EP1267902A1 Cosmetic use of hop and ornithine |
| 01/02/2003 | EP1267900A1 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract |
| 01/02/2003 | EP1267889A1 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| 01/02/2003 | EP1267888A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 01/02/2003 | EP1267882A2 Apoptosis inhibitor with prostaglandin structure |